Leaders in

Contract Manufacturing

20th Floor, Lotus Business Park, Off Andheri Link Road, Andheri (West), Mumbai - 53

Contact No: +91-22-4068 2300 (30 Lines), Fax: +91-22-4068 2323/33, 2673 3687

Website: www. ankurdrugs.com Email: all@ankurdrugs.com

Registered Office

INTRODUCTIONINTRODUCTION

• A Public Limited Company listed at Bombay Stock Exchange & National Stock Exchange of India Limited having a turnover of INR 10675 million and Net profit of INR 894 million

• Engaged in the manufacturing of Pharmaceutical Formulations since 1998.

• Multi location facility having Plants at Daman and Baddi

• The company’s major expansion program with a view to cater the International Market.

• Ankur is privileged of being in the forefront of contract manufacturing with India’s leading and multinational pharmaceutical companies.

• Ankur’s first plant is situated at Daman, which is having dedicated block for General and Beta-lactum products in oral dosage form.

• The Company has set-up two plants spread across “dimensions” at Himachal Pradesh in excise and pollution free zone, amongst lush green surroundings. The main object behind setting up two units was to cater Domestic and International Market.

• Ankur has succeeded to explore and maintain its production target for above 400 different formulations for different dosage forms – viz Tablets, Capsules, Dry Syrups, Liquid Orals, etc.

• Company has already received WHO GMP Certification for its Unit - I at Village Manakpura, Tehsil : Nalagarh, Dist.: Solan, Himachal Pradesh – 173 205.

INTRODUCTIONINTRODUCTION

To manufacture and supply quality healthcare products at reasonable prices to our customers.

“Our focus is to meet and exceed stakeholders expectations.”

Strong Business Ethics

Team of Experienced Pragmatic People.

Transparent Operations

Passion for Performance

High Customer Value

APPROACHES AND VALUESAPPROACHES AND VALUES

• Project envisaged in Jan 2005

• Set up to meet the challenges in the new Taxation scenario

• Capital Investment of US$ 35.00 million = INR 175 Crores

• WHO / GMP approved plant

INFRASTRUCTURE INFRASTRUCTURE

Land Area Twelve Acres

General Block 1 50X40 meters Block : Ground + Service Floor

General Block 2 42X85 meters Block : Ground + Three Floors

Cephalosporin Block 30X45 meters Block : Ground + Three Floors

Beta-Lactum Block 30X45 meters Block : Ground + Three Floors

Warehouse Block 1 50X90 meters Block : Ground + Three Floors

Utilities 35X15 meters Block : Ground + Service Floor

BADDI UNIT –I : OVERVIEWBADDI UNIT –I : OVERVIEW

• Unit is having manufacturing facilities with modular clean room panels for General Products, Beta-lectum Products and Cephalosporin Products in oral dosage forms. Each block is having dedicated Quality Control Laboratories. The manufacturing area of all blocks are maintained at class 100,000.

• In General Block, Oral Liquid filling and packaging line are connected to fully automatic cartoning and case packing machine from Romaco, Italy.

• Betalactum and Cephalosporin Blocks are having low RH (<25%) manufacturing areas with continuous monitoring systems from Rotronic, Switzerland. Both the Dry Syrup filling and packaging lines of Betalactum and Cephalosporin Blocks are having on-line non-destructive leak testing machines for filled and sealed bottles from Bonfiglioli, Italy giving the advantage of 100% check on sealed containers and fully automatic cartoning and case packing machine from Romaco, Italy.

• State-of-the-art technology built-up viz : Capsule Filling Machine, Automatic Tablet Coating Machine from Sejong and Alu Alu Blister Pack Machines from Hoonga, Korea have been installed in all critical area.

BADDI UNIT –I : PRODUCTION FACILITIES :BADDI UNIT –I : PRODUCTION FACILITIES :

GENERAL BLOCK :Tablets (Coated / Uncoated) 3000.00 Capsules 375.00Liquid Orals 150.00

CEPHALOSPORIN BLOCK:Tablets (Coated / Uncoated) 480.00Capsules 144.00Dry - Syrups 24.00Insta use Suspensions 24.00

BETA LACTUM BLOCK:Tablets Uncoated 480.00Capsules 1248.00Dry - Syrups 48.80

Insta use Suspensions 24.00

BADDI UNIT – I: BADDI UNIT – I: INSTALLED CAPACITY p.a ( in million) :INSTALLED CAPACITY p.a ( in million) :

• Designed as per USFDA / MHRA standards

• Capital Investment of US$ 120 million = INR 550 Crores

• Technical arrangement with : BASSAIRE – UK , a leading consulting firm, Engineers & Architect.

INFRASTRUCTUREINFRASTRUCTURE

Land Area Fifteen Acres

General Block 77 x 77 meters Block : Ground + First Floor +

Two Service Floor

Cephalosporin Block 77 x 54 meters Block: Ground + Service Floor

Q.C. Central Warehouse 77 x 24 meters Block : Ground + Three Floor

& Admin Block

Utility Block 67 x 17 meters Block Ground + First Floor

BADDI UNIT –II : OVERVIEWBADDI UNIT –II : OVERVIEW

• There is a high focus onwards automation to avoid human intervention and errors occurred thereon and in the process, various standard machineries are imported to meet the requirements.

• In General Block and Cephalosporin Block Tablet Compression and Capsule Filling machine are from Sejong, Korea. Alu Alu Blister Pack machine from Hoonga, Korea, fully Automatic Strip Pack machine from Siebler, Germany and all packaging lines are connected to fully automatic cartoning and case packing machine from Hoonga and Romaco, Italy.

• In EVT area, single pot manufacturing equipment is from Zanchetta, Italy and fully Automatic Strip Pack machine from Siebler, Germany and fully automatic cartoning and case packing machine from Romaco, Italy.

BADDI UNIT – II : HIGH END TECHNOLOGYBADDI UNIT – II : HIGH END TECHNOLOGY

• Ointment filling line and Sterile Dry Powder filling line from Romaco Macofar, Italy are connected to fully automatic cartoning and case packing machine from Romaco, Italy.

• As a major step towards Ankur’s progress in International market, Trans Dermal Patches (Fentanyl and Cold Fleece) and Oral Strip (Ondansetrone, Donepezil – Hcl, Ketotifen Fumarate, Baclofe, Rivastigmine, Sildenafil Citrate, Glimepiride and Olanzapine) are ready for manufacturing, in technical colaboration with Labtech - Germany and Applied Pharma Research – Switzerland for marketing in India and various South Asian territories. .

BADDI UNIT – II : HIGH END TECHNOLOGYBADDI UNIT – II : HIGH END TECHNOLOGY

• State-of the art technology built-in. High degree of automation which is one of its kind in India and South East Asia, having dedicated manufacturing blocks for General Products and Cephalosporin Products with modular cleanroom panels from Thrislington, U.K and designed as per USFDA/MHRA norms.

• General Block is having manufacturing facility of Tablets, Capsules, Effervescent Tablet, Liquid Injections, Ointments, FFS, Trans Dermal Patches and Oral Film Products.

• Cephalosporin Block is having manufacturing facility of Tablets, Capsules, Dry Syrups and Sterile Dry Powder Injections.

• The Manufacturing areas of Oral Dosage Forms and Ointment are maintained at Class 1,00,000 and manufacturing area of Liquid Injection and Sterile Dry Powder Injections are maintained at class 100.

BADDI UNIT – II : PRODUCTION FACILITIESBADDI UNIT – II : PRODUCTION FACILITIES

GENERAL BLOCKTablets - coated / uncoated 9,000.00Capsules 900.00Liquid Injectables 144.00Effervescent Tablets 300.00Sachets 60.00Ointments/Creams 30.00Form Fill and Seal (FFS) 30.00

CEPHALOSPORIN BLOCKTablets coated / uncoated 1200.00 Capsules 540.00 Dry Syrups 48.00Dry powder Injectables 30.00

BADDI UNIT – iI: BADDI UNIT – iI: INSTALLED CAPACITY p.a ( in million) :INSTALLED CAPACITY p.a ( in million) :

• Mr. Purnandu Jain - Chairman and Managing Director, is a qualified Chartered Accountant having over Ten years of experience in Pharma manufacturing business. He has successfully turned around the company and improved its performance many fold.

• Mr. Girraj Vijayvargiya - Executive Director, is also a qualified Chartered Accountant having over 10 years experience in Pharmaceutical Project Finance and Purchase.

• Mr. A. Hossain - President (Technical & Projects), M. Pharm. Having over 28 years of experience in Projects, Manufacturing, Plant Administration.

• Mr. Jayesh Trivedi – Chief Operating Officer, B. Pharm. Having over 30 years of experience in techno commercial, outsourcing & business development, mainly responsible for regulatory affairs & International business.

• Mr. M. B. Sawant - Sr. Vice President (Commercial), M.B.A. Production, having about 30 Years experience in PPC and Supply Chain in pharmaceutical industry.

• Mr. Sunil Soni - Vice President (Operations), M. Pharm. Having over 17 years experience in Manufacturing and Plant Administration.

• Mr. Sardul Singh - General Manager (Administration) having more than 45 years experience in the Industry.

• Mr. Ashok Mehta - General Manager (Quality Assurance), M. Pharm having more than 26 years of experience in the Industry.

• Abbott India Limited

• Blue Cross Laboratories Limited

• Cipla Limited

• Dr. Reddy’s Laboratories Limited

• Hindustan Antibiotics Limited

• Hovid

• Karnataka Antibiotics & Pharmaceuticals Limited

• Novartis India Limited

SOME OF OUR VALUED CUSTOMERS SOME OF OUR VALUED CUSTOMERS (as per alphabetical order)(as per alphabetical order)

• Piramal Healthcare Limited

• Pfizer India Ltd

• Rajasthan Drugs & Pharmaceuticals Limited

• Ranbaxy Laboratories Limited

• Sandoz Private Limited

• Sanofi Aventis

• Torrent Pharma Limited

• USV Limited

• Fentanyl Transdermal Patch – A breakthrough in pain management therapy in treatment of cancer

• High end pain management drug

• Painless dosage form

• Reduced dosage form due to quick absorption and high efficacy

• Fentanyl a potential goldmine

• Ankur has exclusive manufacturing and marketing rights of Fentanyl in territories such as South –East Asia, South Africa, East Africa and Central Africa

ANKUR REVOLUTIONIZING CANCER TREATMENTANKUR REVOLUTIONIZING CANCER TREATMENT

ANOTHER FIRST FOR ANKURANOTHER FIRST FOR ANKUR

• Ankur will be the first ever Indian company to launch “Rapid Film” in India and other territories. The company has been granted exclusive manufacturing rights for initial 15 years for territories viz. India, Bangladesh, Sri Lanka, Pakistan and Afghanistan

• Is a new concept in oral dosage form and medication.

• It is a novel, non-muco adhesive fast dissolving oral dosage form.

• It releases the drug in the mouth and initiates buccal absorption, within no time.

• Any drug up to 50 mg per strip can be easily taken up through this dosage form. The film is either packed in conventional ways or in elegant single smart card design, such as credit card format.

• Ankur has associated with Optimags Germany for an exclusive special coating lines and has imported the latest technology in Packing lines from “Siebler” (Romaco Group) Germany viz Rapid film for Ondasetrone, Donepezil-Hcl, Ketotifen Fumarate, Baclofe, Rivastigmine, Sildenafil Citrate, Glimepiride and Olanzapine.

FINANCIAL HIGHLIGHTS OF LAST 5 YEARS

SUMMARY OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED

(Rs. Crores)

PARTICULAR'S 31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010

           

Net Sales/Income from Operations 136.45 373.24 673.50 965.32 1067.53

Other Income 0.07 0.32 1.50 2.94 1.63

Increase in Inventory 0.40 6.62 3.30 46.34 3.72

Total Income 136.92 380.18 678.30 1,014.60 1072.88

           

TOTAL EXPENDITURE 

Materials Consumed 104.16 302.76 542.19 784.42 799.38

Manufacturing Expenses 8.10 15.98 21.67 33.02 39.52

Administrative, Sales and Other Expenses 2.66 3.15 6.16 14.98 19.14

           

Total Expenditure 114.92 321.89 570.02 832.42 858.04

FINANCIAL HIGHLIGHTS OF LAST 5 YEARS

 

SUMMARY OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED (Rs. Crores)

PARTICULAR'S 31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010

           

Profit before depreciation, finance cost and tax 22.00 58.29 108.28 182.18 214.84Less: Depreciation 2.50 6.01 8.40 20.67 26.77Less: Interest and Financial Charges 4.08 12.92 24.86 54.10 79.00Less: Prov. for exch. diff. on foreign currency loans - - - 26.13 (16.23)Less: Prov for premium on redemption of FCCB's - - - 20.94 3.20Less: Other Misc. Provisions - - - 1.42 (1.33)         

Profit before tax 15.42 39.36 75.02 58.92 123.43           

Less: Provision for taxation- Current Tax 1.36 4.25 8.71 7.30 21.00- Deferred Tax 0.05 2.32 2.74 14.39 13.00- Fringe Benefit Tax 0.03 0.05 0.07 0.10 -

           

Profit after tax 13.98 32.74 63.50 37.13 89.43         

Dividend (Including Dividend Tax and prov for prev. yr.) 1.62 2.22 5.65 5.01 -           

Earning per share- Basic (In Rs.) 14.72 34.43 53.79 19.94 46.24

- Diluted (In Rs.) - 17.62 23.50 23.61 37.63

SUMMARY OF BALANCE SHEET AS AT(Rs. Crores)

PARTICULAR'S 31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010           

Sources of Funds          

Shareholders' Funds          

Equity Share Capital 9.50 10.56 12.70 18.61 19.34Equity Share Application and Warrants --- 8.07 8.72 10.02 ---Reserve & Surplus 19.32 94.53 198.04 243.01 345.23Miscellaneous Expenditure (0.25) (0.37) (0.52) (0.26) -Deferred Tax Liability 4.82 7.14 9.88 24.27 37.27

Net Worth

33.39

119.93

228.82

295.65 401.84

Loan Funds          Term Loan (Secured) 42.60 145.20 236.89 205.28 258.65

Working Capital Loan 26.15 82.25 168.33 274.76 392.52

Loan from Directors (Unsecured) 2.41 1.87 1.33 1.40 1.50

Loan from Others (Unsecured) 39.86 66.90 76.77 116.62 114.05

Foreign Currency Convertible Bonds - 55.07 134.16 145.43 125.71           

Current Liabilities & Provisions        

Current Liabilities 7.11 26.40 38.78 60.57 96.88

Provisions 4.40 6.69 13.68 33.35 52.54           

TOTAL LIABILITIES 156.23 504.81 899.41 1,134.27 1443.69

SUMMARY OF BALANCE SHEET AS AT(Rs. Crores)

PARTICULAR'S 31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010

           

Application of Funds          

Fixed Assets          

Gross Block 41.15 127.96 228.04 390.65 775.16

Less: Depreciation 8.16 15.58 23.88 44.50 71.28

Net Block 32.99 112.38 204.16 346.15 703.88

Capital Work-in-progress 65.61 245.03 331.49 266.10 22.94

         

Investments 0.01 0.02 5.24 3.74 0.48

           

Current Assets, Loans and Advances          

Inventories 24.56 62.18 123.15 212.77 322.97

Sundry Debtors 28.35 76.90 163.91 281.14 357.69

Cash and Bank Balances 1.74 2.56 59.06 15.84 7.01

Loans and Advances 2.97 5.74 12.40 8.53 28.72

         

TOTAL LIABILITIES 156.23 504.81 899.41 1,134.27 1443.69

         

Current Ratio 1.53 1.28 1.62 1.41 1.32 : 1

Debt Equity Ratio 2.88 2.64 2.53 2.38 2.22 :1

SUMMARY OF PROJECTIONS

(Rs. Crores)2010 - 11 2011 - 12 2012 - 13 2013 -14 2014 - 15

Net Sales 1350.00 1500.00 1600.00 1700.00 1750.00

EBI DTA 243.00 270.00 288.00 306.00 315.00

PBT 130.00 150.00 175.00 190.00 200.00

PAT 100.00 120.00 135.00 145.00 150.00

PROFITABILITY RATIO %OPERATING PROFT MARGIN 18% 18% 18% 18% 18%

NET PROFIT MARGIN 7.41% 8% 8.44% 8.53% 8.57%

CASH PROFIT MARGIN 11.11% 11.33% 11.50% 11.47% 11.43%